REFERENCES
1. Karwi QG, Ho KL, Pherwani S, Ketema EB, Sun Q, Lopaschuk GD. Concurrent diabetes and heart failure: interplay and novel therapeutic approaches. Cardiovasc Res. 2022;118:686-715.
3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79:e263-421.
4. Mcdonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-726.
5. Bayes-genis A, Docherty KF, Petrie MC, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the heart failure association of the ESC. Eur J Heart Fail. 2023;25:1891-8.
6. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-61.
7. Solomon SD, Mcmurray JJ, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089-98.
8. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757-67.
9. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396:819-29.
10. Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27:1954-60.
11. Kent DM, Paulus JK, Van Klaveren D, et al. The predictive approaches to treatment effect heterogeneity (PATH) statement. Ann Intern Med. 2020;172:35-45.
12. Bai Q, Chen H, Gao Z, et al. Advanced prediction of heart failure risk in elderly diabetic and hypertensive patients using nine machine learning models and novel composite indices: insights from NHANES 2003-2016. Eur J Prev Cardiol. 2026;33:53-63.
13. Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378.
14. Moons KGM, Damen JAA, Kaul T, et al. PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods. BMJ. 2025;388:e082505.
15. Austin PC, White IR, Lee DS, Van Buuren S. Missing data in clinical research: a tutorial on multiple imputation. Can J Cardiol. 2021;37:1322-31.
16. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565-74.
17. Liu X, Xie Z, Zhang Y, et al. Machine learning for predicting in-hospital mortality in elderly patients with heart failure combined with hypertension: a multicenter retrospective study. Cardiovasc Diabetol. 2024;23:407.
18. Chen Z, Cheng J, Huang C, et al. Machine learning-based prediction of mortality and hospitalization in diabetic patients with heart failure with preserved ejection fraction: the GUARDIAN-P risk score. Eur Heart J Digit Health. 2026;7:ztag083.
19. Vest AR, Didomenico RJ, Lichtenstein L, et al. Malnutrition and Cachexia in Inpatients With Acute Cardiac Conditions: A Scientific Statement From the American Heart Association. Circulation. 2026;153:e1078-105.
20. Von Haehling S, Ebner N, Dos Santos MR, Springer J, Anker SD. Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol. 2017;14:323-41.
21. Martinez FA, Serenelli M, Nicolau JC, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation. 2020;141:100-11.
22. Engström A, Söderling J, Hviid A, et al. Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study. Eur Heart J Cardiovasc Pharmacother. 2024;10:432-43.
23. Mone P, Guerra G, Lombardi A, et al. Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease. Pharmacol Res. 2024;200:107055.
24. Mone P, Lombardi A, Kansakar U, et al. Empagliflozin improves the MicroRNA signature of endothelial dysfunction in patients with heart failure with preserved ejection fraction and diabetes. J Pharmacol Exp Ther. 2023;384:116-22.
25. Fountoulakis N, Miyamoto Y, Pavkov ME, Karalliedde J, Maltese G. Pathophysiology of vascular ageing and the effect of novel cardio‐renal protective medications in preventing progression of chronic kidney disease in people living with diabetes. Diabet Med. 2024;42:e15464.
26. Faridi KF, Dayoub EJ, Ross JS, Dhruva SS, Ahmad T, Desai NR. Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure. J Am Coll Cardiol. 2022;79:2516-25.
27. Atzema CL, Austin PC, Yu B, et al. Effect of early physician follow-up on mortality and subsequent hospital admissions after emergency care for heart failure: a retrospective cohort study. Can Med Assoc J. 2018;190:E1468-77.
